secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2022-06-22T23:59:59+00:00
Accession:  0001651308-22-000089
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene's NMPA accepts sBLA for tislelizumab in first-line PD-L1+ gastric cancer
--------------------------------------------------------------------------------

- CDE of NMPA accepted sBLA for tislelizumab + chemo as first-line treatment for advanced G/GEJ adenocarcinoma with PD-L1 expression.
- Submission supported by interim analysis of global Phase 3 RATIONALE 305 trial showing survival benefit.
- This is the 10th regulatory submission for tislelizumab in China; it is already approved for 9 indications there.
- Tislelizumab is also under FDA and EMA review for ESCC and NSCLC; partnered with Novartis in North America, Europe, Japan.
- Gastric cancer is the 2nd leading cause of cancer death in China; few options exist for metastatic disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130822000089/0001651308-22-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130822000089/bgne-20220621.htm
  HTML page:      https://secwatch.observer/filing/0001651308-22-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer